A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation
Isabelle Bence‐Bruckler(University of Ottawa), Lothar Huebsch(University of Ottawa), Harold Atkins(University of Ottawa), Sheryl McDiarmid(Ottawa Hospital), Linda Hamelin(Ottawa Hospital), George Perry(The University of Texas at San Antonio), P. Genest(University of Ottawa), H. S. Hopkins(University of Ottawa), Christopher Bredeson
Cited by 48
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents
|Cancer Cell|2003|850
Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus
|Nature Medicine|2000|816
Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains.
|Proceedings of the National Academy of Sciences|1987|621
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
|New England Journal of Medicine|2018|598